Nektar Therapeutics (NKTR) Gross margin 2016–2025
Nektar Therapeutics (NKTR) gross margin by fiscal year — reported gross profit divided by reported revenue.
100.0%FY2025 · since FY2016: 81.7% → 100.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 100.0% | +31.2 pp |
| FY2024 | 68.8% | +6.3 pp |
| FY2023 | 62.5% | -14.0 pp |
| FY2022 | 76.5% | +0.9 pp |
| FY2021 | 75.6% | -11.7 pp |
| FY2020 | 87.3% | +5.9 pp |
| FY2019 | 81.4% | -16.6 pp |
| FY2018 | 98.0% | +7.9 pp |
| FY2017 | 90.1% | +8.3 pp |
| FY2016 | 81.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NKTR financial trends
NKTR RevenueNKTR Net incomeNKTR Net marginNKTR Gross profitNKTR Operating incomeNKTR Operating marginNKTR Operating cash flowNKTR Free cash flowNKTR Capital expendituresNKTR Return on equityNKTR Stock buybacksNKTR Dividends paidNKTR Total assetsNKTR Total liabilitiesNKTR Shareholders’ equityNKTR overview →